A feasibility study of intensive CAF as outpatient adjuvant therapy for stage II breast cancer in a cooperative group: CALGB 8443

Daniel R. Budman, Ann Hughes Korzun, Joseph Aisner, Jerry Younger, Richard Silver, Mary Costanza, Mary Alice Rice, William Wood

Research output: Contribution to journalArticle

9 Scopus citations


In preparation for a national Phase III say of dose and dose intensity in the treatment of node-positive, Stage II adenocarcinoma of the female breast, CALGB instituted a pilot study of intensive intravenous outpatient CAF (cyclophosphamide, Adriamycin, 5-fluorouracil) for four months. This study was designed to give full doses of drugs without dose reduction for hematologic toxicity. In order to evaluate the feasibility of physician and patient compliance with a potentially toxic therapy, a multi-institution pilot study was performed. lEs protocol demonstrated that a cooperative group could deliver toxic drug doses to outpatients with a median of 98% of cyclophosphamide, 97% of Adriamycin (doxorubicin), and 91% of 5-fluorouracil administered on schedule. Major side effects, as expected, were leukopenia, nausea, and vomiting. Disease-free survival is at least equivalent to that observed in previous studies.

Original languageEnglish (US)
Pages (from-to)571-575
Number of pages5
JournalCancer Investigation
Issue number6
Publication statusPublished - Jan 1 1990


All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this